BioSpace News Archive

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced its plans to release financial results for its second quarter ended June 30, 2022 after the close of trading on August 9, 2022.

SCYNEXIS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s submission of a supplemental New Drug Application (sNDA) to expand the label of BREXAFEMME® (ibrexafungerp tablets) to include the prevention of recurrent vulvovaginal candidiasis (RVVC).

Catalyst Biosciences, Inc. published a detailed investor presentation in advance of its upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022.

CorMedix Inc. today announced that it will report its financial results for the second quarter ended June 30, 2022, before the market open on Thursday, August 11, 2022, and will host a corporate update conference call at 8:30am Eastern Time.

ALR Technologies SG Pte. Ltd, the diabetes management company, announces the Company has received manufacturing approval from Infinovo Medical Co., Ltd. to place the first purchase order for the GluCurve Pet CGM with an expected delivery date of October 2022.

Qualigen Therapeutics, Inc. today announces it has completed its in vivo efficacy analysis of QN-247 in solid tumors.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced their ongoing collaboration with the International Foundation for Gastrointestinal Disorders (IFFGD) for Gastroparesis Awareness Month celebrated in August each year.

Nuvectis Pharma, Inc. today announced the closing of its previously announced private placement of 1,924,689 shares of common stock.

Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today provided a business update and reported financial results for the fiscal year ended April 30, 2022.

Rubedo Life Sciences , a biopharmaceutical company pioneering first-in-class therapies for chronic age-related diseases targeting the senescent cells that drive cellular aging, today announced the appointment of veteran biotech executives Ali Siam as Chief Business Officer and seasoned drughunter Ofir Moreno, Ph.D., as Senior Vice President, Drug Discovery.